Pfizer makes and sells medicines and vaccines—think of it as a giant pharmacy supplier for everything from COVID shots to cancer pills, selling to hospitals, governments, and drugstores worldwide.
Money comes from recurring drug and vaccine sales, with gross margins around 71% and net margins near 7% in the latest TTM—high-margin, repeat-purchase revenue, though quarterly net income swung to a loss in mid-2026.
Patents and scale protect Pfizer, but key exclusivities are fading—generic competition from Teva and Viatris, plus biosimilars from Amgen and Samsung Bioepis, erode blockbusters like Eliquis and Ibrance.
Hold (sector percentile 36) — value B, growth D, profitability B+, momentum C, revisions B. Updated daily, sector-relative, identical for every user.
